title: Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups.
abstract: Human narcolepsy-cataplexy, a sleep disorder associated with a centrally mediated hypocretin (orexin) deficiency, is tightly associated with HLA-DQB1*0602. Few studies have investigated the influence that additional HLA class II alleles have on susceptibility to this disease. In this work, 1,087 control subjects and 420 narcoleptic subjects with cataplexy, from three ethnic groups, were HLA typed, and the effects of HLA-DRB1, -DQA1, and -DQB1 were analyzed. As reported elsewhere, almost all narcoleptic subjects were positive for both HLA-DQA1*0102 and -DQB1*0602. A strong predisposing effect was observed in DQB1*0602 homozygotes, across all ethnic groups. Relative risks for narcolepsy were next calculated for heterozygous DQB1*0602/other HLA class II allelic combinations. Nine HLA class II alleles carried in trans with DQB1*0602 were found to influence disease predisposition. Significantly higher relative risks were observed for heterozygote combinations including DQB1*0301, DQA1*06, DRB1*04, DRB1*08, DRB1*11, and DRB1*12. Three alleles-DQB1*0601, DQB1*0501, and DQA1*01 (non-DQA1*0102)-were found to be protective. The genetic contribution of HLA-DQ to narcolepsy susceptibility was also estimated by use of lambda statistics. Results indicate that complex HLA-DR and -DQ interactions contribute to the genetic predisposition to human narcolepsy but that additional susceptibility loci are also most likely involved. Together with the recent hypocretin discoveries, these findings are consistent with an immunologically mediated destruction of hypocretin-containing cells in human narcolepsy-cataplexy.
authors.affiliation: Center For Narcolepsy, Stanford University, Department of Psychiatry and Behavioral Sciences, Palo Alto, CA 94304, USA. mignot@leland.stanford.edu
authors.forename: E
authors.initials: E
authors.lastname: Mignot
authors.forename: L
authors.initials: L
authors.lastname: Lin
authors.forename: W
authors.initials: W
authors.lastname: Rogers
authors.forename: Y
authors.initials: Y
authors.lastname: Honda
authors.forename: X
authors.initials: X
authors.lastname: Qiu
authors.forename: X
authors.initials: X
authors.lastname: Lin
authors.forename: M
authors.initials: M
authors.lastname: Okun
authors.forename: H
authors.initials: H
authors.lastname: Hohjoh
authors.forename: T
authors.initials: T
authors.lastname: Miki
authors.forename: S
authors.initials: S
authors.lastname: Hsu
authors.forename: M
authors.initials: M
authors.lastname: Leffell
authors.forename: F
authors.initials: F
authors.lastname: Grumet
authors.forename: M
authors.initials: M
authors.lastname: Fernandez-Vina
authors.forename: M
authors.initials: M
authors.lastname: Honda
authors.forename: N
authors.initials: N
authors.lastname: Risch
mesh_terms: D001741:Black or African American; D000483:Alleles; D044466:Asian People / Q000235:genetics; D044383:Black People / Q000235:genetics; D002385:Cataplexy / Q000235:genetics*; D005006:Ethnicity / Q000235:genetics*; D005787:Gene Frequency; D005802:Genes, MHC Class II; D020022:Genetic Predisposition to Disease; D006683:HLA-DQ Antigens / Q000235:genetics*; D006684:HLA-DR Antigens / Q000235:genetics*; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007564:Japan / Q000208:ethnology; D009290:Narcolepsy / Q000235:genetics*; D012307:Risk Factors; D044465:White People / Q000235:genetics
chemical_list: D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens